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This survey describes the experiences of patients diagnosed with pulmonary fibrosis,
focusing on the issues of patient education and resources. A survey of 52 defined-choice
and open-ended questions regarding the diagnosis and management of pulmonary fibrosis
was delivered. A total of 1448 respondents comprised the study group. Two-thirds of
respondents reported a clear lack of information and resources on pulmonary fibrosis at
the time of diagnosis. Less than half of respondents reported they felt well-informed about
treatment options, the role of supplemental oxygen, pulmonary rehabilitation, and
transplantation. These results suggest there is a substantial need for improved patient
education regarding the diagnosis and management of pulmonary fibrosis.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Few diagnoses in pulmonary medicine generate as much
concern among both patients and their physicians asElsevier Ltd. All rights reserved.
206 4694;
ucsf.edu (H.R. Collard).pulmonary fibrosis. An accurate diagnosis is challenging as
it requires the skilled integration of clinical, radiographic
and histopathologic findings that are rarely textbook in
presentation.1 The most common cause of pulmonary
fibrosis, idiopathic pulmonary fibrosis pulmonary fibrosis is
a devastating diagnosis, as the disease has no effective
therapy and its prognosis is uniquely poor.2–7
Significant advances have been made in the diagnosis
of pulmonary fibrosis, in particular IPF, in the last decade.
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characterized by usual interstitial pneumonia pattern on
surgical lung biopsy,2 the demonstration that many patients
with IPF can be accurately diagnosed without a surgical lung
biopsy in the right clinical context,8,9 and the establishment
of a clearer understanding of prognosis and predictors of
survival.5–7,10–12 It is unclear how these advances have
impacted community practice, and whether clinicians are
translating this knowledge to their patients with pulmonary
fibrosis.
The coalition for pulmonary fibrosis (CPF), a non-profit
public benefit organization, developed a research question-
naire to collect information from its members regarding
patient experiences with the management of IPF and other
forms of pulmonary fibrosis. A wide range of topics was
covered, with a major focus on the attitudes and experi-
ences of patients diagnosed with pulmonary fibrosis with
regards to diagnosis and management of their disease. This
paper summarizes the results of this sample survey.Table 1 Demographics.
Demographic (n ¼ 1448) Value
Median age at time of survey (years) 65
o50 12.5%
50–59 20.8%
60–69 29.3%
X70 35.5%
Male sex 54.3%
White race 90.2%
Cigarette use
Current 3.2%
Former 65.7%
Never 30.7%
Gastroesophageal reflux disease 44.2%
Exposures
Polluted air 30.2%
Asbestos 22.4%
Molds 19.7%
Pesticides, chemicals, fertilizers 10.5%
Dusts, fibers 10.8%
Family history of pulmonary fibrosis 11.9%
Year of diagnosis
o2000 23.9%
2000–2001 24.8%
2002–2003 39.9%
2004 10.2%Methods
The CPF is a nonprofit organization founded to further
patient and physician support and education, and to
enhance research efforts in pulmonary fibrosis. The CPF is
governed by pulmonologists, patients, investigators and
advocacy organizations. Membership is free, and most
members learn of the CPF through seminars, word of mouth
or the Internet.
A patient questionnaire was developed in conjunction
with clinicians experienced in issues surrounding the
management of pulmonary fibrosis in order to better
understand the experiences of patients with this condition.
The questionnaire was designed to collect the following
information: demographics, family history, potential envir-
onmental exposures, diagnostic testing performed, treat-
ments prescribed, and patient attitudes regarding the
adequacy of information received from health care provi-
ders concerning the management of their disease. Questions
were created by the authors based on informal interviews
with patients and family members of patients including
those participating in CPF-sponsored support groups. Draft
questions were reviewed by patients and families for clarity,
and edits were made by two authors (MM, BC) according to
industry standards.
Funding for this project was provided by the DuBrul
Family Fund and the family of Helen and Michael Galvin. The
questionnaire was distributed to over 2000 members (all
patients and caregivers of current and deceased patients for
which addresses were available) between July 2003 and
December 2004. The questionnaire was sent both in paper
form and via email with a link to a web-based survey site.
The survey was also made available to CPF members online
and in paper form through the CPF website, sponsored
seminars and institutional partners.
Completed questionnaires were compiled by Michaels
Opinion Research, Inc. (MM, BC), an independent research
firm experienced in conducting sample surveys. Results
reported in this publication are based on the responses from
living patients or caregivers of living patients. Two authors
(HRC, MIS) reviewed the raw data and directed the analysis.Results were tabulated as a whole as well as by age and year
of diagnosis. Statistical analysis was performed using
WinCross cross-tabulation software. Comparisons across
groups (e.g. by year of diagnosis) were made using
independent t-tests for means and Z-tests for independent
proportions. Full results of the survey are published in the
electronic appendix to this publication. This project was
approved by the University of California San Francisco
Committee on Human Research.Results
Demographics
Responses were received from 1583 individuals. The
majority of respondents were current patients (79.0%), the
minority were caregivers of current (12.4%) or deceased
patients (8.5%). There were 1448 current patients or
caregivers of current patients who responded (current
patients (n ¼ 1251), caregivers responding on behalf of
current patients (n ¼ 197)), and these make up the study
cohort. Responses were generally similar between patients
and caregivers and are reported together throughout this
publication.
The median age of respondents was 65 years (Table 1).
There were slightly more men than women (1.2:1), and the
vast majority were white (90.2%). Sixty-nine percent (68.9%)
reported a history of cigarette use (mean 24.5 years),
including only 3.2% currently smoking. Twenty-four percent
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2000.
A diagnosis of gastroesophageal reflux disease was
reported by 44.2% of respondents. A wide variety of
potential environmental exposures were reported by a
minority. A family history of pulmonary fibrosis in at least
one blood relative was reported by 11.9%. The mean age of
diagnosis for relatives was 63.5 years.
Education and Resources
Sixty-four percent of respondents (63.5%) either somewhat
or strongly agreed with the statement that there was a clear
lack of information and resources about pulmonary fibrosis
available at the time of their diagnosis (Table 2). Slightly
over half (51.2%) reported being generally or very well
informed about treatment options for pulmonary fibrosis at
the present time. Fewer reported being generally or very
well informed regarding the benefits of pulmonary rehabi-
litation (38.7%), managing supplemental oxygen (39.0%),
nutrition (42.5%) and the risks and benefits of lung
transplantation (32.5%). More recently diagnosed and older
respondents reported being significantly less well informed
about these issues (Table 2).
Experience with Diagnosis
Fifty-five percent (54.6%) of respondents reported at least a
1-year delay between the earliest indications of a potential
breathing problem and the diagnosis of pulmonary fibrosis.
Initial incorrect diagnosis was reported frequently:
bronchitis (18.5%), asthma (14.1%) chronic obstructiveTable 2 Patient education and resources.
Group (n) Agree there was a
lack of information/
resources on
pulmonary fibrosis at
time of diagnosis (n)
Generally or very wel
Treatment Reha
Total (1448) 63.5% (919) 51.2% (741) 38.7%
Year of diagnosis
o2000 (347) 68.3% (237) 55.0% (191) 47.0%
2000–2001 (359) 63.0% (226) 58.2% (209)d 43.2%
2002–2003 (578) 61.4% (355)a 49.1% (284) 34.4%
2004 (147) 65.3% (96) 32.0% (47)e 24.5%
Age of time of survey
o50 (181) 75.1% (136)b 46.4% (84) 40.3%
50–59 (301) 68.1% (205)c 53.5% (161) 38.2%
60–69 (424) 61.6% (261) 54.0% (229) 40.6%
X70 (514) 58.8% (302) 49.6% (255) 37.0%
a ¼ Po0.05 compared to year o2000.
b ¼ Po0.05 compared to ages 60–69 and X70.
c ¼ Po0.05 compared to age X70.
d ¼ Po0.05 compared to year 2002–2003.
e ¼ Po0.05 compared to all other years.
f ¼ Po0.05 compared to yearo2000 and 2000–2001.
g ¼ Po0.05 compared to age 50–59 and 60–69.
h ¼ Po0.05 compared to all other ages.pulmonary disease (7.5%), emphysema (6.6%) heart disease
(5.0%). Thirty-eight percent (38.2%) of respondents reported
seeing 3 or more physicians before the diagnosis of pulmonary
fibrosis was established. Fifty-three percent (53.2%) sought a
second opinion. Eighty-four percent (84.4%) consulted a
pulmonologist at some point during their diagnostic evalua-
tion. Sixty-four percent of respondents (64.4%) reported
being questioned about a family history of lung or respiratory
disease. Only 27.5% recall having been told that genetic
factors may predispose to pulmonary fibrosis.
Half of all respondents (50.2%) reported having a surgical
lung biopsy. Surgical lung biopsy was less commonly reported
the more recent the diagnosis. A minority reported having
undergone bronchoscopy (21.5%).Experience with Treatment
Overall, 74.7% of respondents reported current pharmaco-
logic therapy for pulmonary fibrosis. The most common
reasons given for not receiving pharmacologic therapy were
fear of side effects (25.9%), ineffectiveness of therapy
(22.7%), no treatment prescribed (23.3%), or early or stable
disease (21.6%). The percentage of respondents reporting
pharmacologic therapy was significantly less the more
recent the diagnosis (Fig. 1).
Fifty percent of respondents (49.8%) reported currently
taking prednisone for the treatment of pulmonary fibrosis.
Another 20.9% had been prescribed prednisone in the past.
A minority reported receiving cyclophosphamide (3.2%
current, 5.8% former), azathioprine (10.2% current, 8.7%
former) or colchicine (6.0% current, 6.5% former). Inter-
feron gamma 1–b use was reported by 28.5% of respondentsl-informed about (n)
b Oxygen Nutrition Transplant
(560) 39.0% (565) 42.5% (615) 32.5% (471)
(163) 48.1% (167) 48.4% (168) 40.3% (140)
(155) 43.7% (157) 45.7% (164) 40.1% (144)
(199)e 33.0% (191)f 38.6% (223)f 26.6% (154)e
(36e 27.9% (41)f 34.0% (51)f 18.4% (27)e
(73) 37.0% (67) 43.1% (78) 38.7% (70)
(115) 35.9% (108) 46.8% (141) 37.2% (112)
(172) 41.7% (177) 45.0% (191) 35.8% (152)
(190) 40.1% (206) 38.1% (196)g 24.9% (128)h
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Figure 1 Percentage of respondents reporting no pharmacologic therapy by year of diagnosis. Significantly more respondents report
no pharmacologic therapy for their disease the more recent the diagnosis (**Po0.01, *Po0.05).
Pulmonary fibrosis survey 1353(20.9% current, 7.7% former). A number of respon-
dents (24.4%) reported the use of herbs or nutritional
supplements.
Oxygen use was reported by 60.9% of respondents.
Pulmonary rehabilitation and physical therapy referrals
were reported by a minority of patients (31.8% and 23.9%).
Behavioral health counseling referrals were uncommonly
reported. Transplantation was discussed with the majority
of respondents (58.7%).Discussion
The results of this sample survey provide important insight
into the experiences and attitudes of patients with
pulmonary fibrosis. Despite continued attempts by the
pulmonary community to clarify issues surrounding the
diagnosis and treatment of this condition, including a joint
ATS/ERS consensus statement on the diagnosis and manage-
ment of IPF published in 2000,2 this survey suggests there is
a continued failure on the part of clinicians to educate
patients to their diagnosis. There are several reasons why
patients may feel so ill-informed. Despite the best effort of
the medical community to educate patients, many patients
will require time to accept the diagnosis and repetition
of information regarding its diagnosis and management
to fully understand the implications. The perception of
being uninformed may result more from these issues than
a failure on the part of the treating physician. Nonetheless,
the fact that over half of survey respondents reported
a clear lack of information about pulmonary fibrosis
at the time of diagnosis and felt poorly informed about
important non-pharmacological management options is
unacceptable.
Two other findings deserve mention. First, approximately
half of respondents reported undergoing a surgical lung
biopsy for the diagnosis of their condition. While these data
are patient-reported and therefore open to criticism, this
percentage is in keeping with data that suggest approxi-
mately half of patients with IPF can be diagnosed clini-
cally.8,9 Second, the majority of respondents (71%) reported
current or prior treatment with prednisone. Only a minorityreported receiving cytotoxic agents such as cyclophospha-
mide or azathioprine. Approximately 30% reported current
or prior treatment with interferon gamma 1-b. Although
these results may be due to treatment bias in our responding
population, they suggest that the ATS/ERS recommendation
for combined therapy with prednisone and cytotoxic agents
may not be commonly followed, and that many patients are
receiving off-label investigation agents. Third, the percen-
tage of respondents reporting no pharmacologic therapy
increased significantly the more recent the diagnosis.
Patients and physicians appear to be deciding to forego
medical therapy more frequently than in the past. The data
do not offer an explanation for this observation.
This project represents the first large-scale survey of
patient experiences and perceptions regarding the diagnosis
and treatment of pulmonary fibrosis published to date. Two
surveys of physicians have been published in the last 20 years.
A small survey of physicians was conducted in 1989 to describe
approaches to the management of interstitial lung disease,
but only included 25 respondents.13 More recently, a survey of
physicians in the United Kingdom compiled 588 patients with
IPF (termed cryptogenic fibrosing alveolitis) and described
their presentation, diagnosis and initial management.14
Importantly, the case definition of cryptogenic fibrosing
alveolitis required only chest radiographic findings but not
computed tomography or pathology, thereby likely including
other histopathologic expressions of idiopathic interstitial
pneumonia. The authors reported that the vast majority (88%)
of patients were diagnosed without surgical lung biopsy, and
nearly half (48%) of patients were never treated.
There are important limitations to this current survey that
limit and qualify any conclusions drawn. First and foremost
are issues of sampling. CPF members are self-identified as
having pulmonary fibrosis; no confirmation of the diagnosis
can be obtained. It is important that the results of this survey
not be directly extrapolated to the population of patients with
well-defined IPF. In addition, this survey employs non-
probability sampling, which introduces potential sampling
bias. Unfortunately, probability sampling of pulmonary fibrosis
patients is impossible as there is no central registry from
which to sample. Both of these issues impact the general-
izability (i.e. external validity) of the results.
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results of a sample survey because the population of non-
responders may have substantial differences from the
population of responders (e.g. younger, less dissatisfied,
less educated). In this sample survey, the response rate
approached 50%. While this percentage is higher than many
medical opinion surveys report, a substantial number of non-
respondents remain.
Third, the information obtained from respondents may be
inaccurate (misinformation bias). Respondents may not
correctly understand the subject matter of the question
(e.g. transbronchial lung biopsy may be confused for a
surgical lung biopsy), or respondents may not recall events
accurately. Finally, this survey does not formally assess
patients’ quality of life and cannot comment on the
impact of patient perceptions on this important outcome
measure.15,16
These potential sources of error are common to surveys
and cannot be completely eliminated. Nonetheless, this
survey’s results suggest important findings, most promi-
nently, an unacceptable failure in patient education
regarding the diagnosis of pulmonary fibrosis. These results
should prompt academic and practicing physicians, patients,
and patient advocates to work together to better define and
disseminate information about pulmonary fibrosis, and
motivate providers to redouble efforts to educate their
patients with pulmonary fibrosis about the diagnosis and
management of their disease.
Appendix A. Supplementary Materials
Supplementary data associated with this article can be
found in the online version at doi:10.1016/j.rmed.2006.
10.002.
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